GLP-1 & compounded medication availability in Vermont (2026)

Vermont writes more of its pharmacy expectations into formal rule than most small states, and its board refreshed its administrative rules as recently as February 2026. It also asks something specific of compounders: an out-of-state pharmacy that compounds registers under a compounding specialty designation, whatever it happens to ship. None of that changes what reaches a Vermont address through OrderlyMeds: eight lines ship, and two honestly do not.

Baseline state

Availability facts last reviewed: November 16, 2026

Vermont availability, all ten lines

Availability of all ten OrderlyMeds product lines in Vermont, with typical delivery times and notes
Product lineAvailable in Vermont?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Ships via nonresident-registered partner pharmacies.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days One national price, every dose.
NAD+ Yes 8–10 business days Same telehealth ordering flow as every state.
Sermorelin Yes 8–10 business days Dispensed by partner pharmacies registered for Vermont.
Glutathione No N/A A catalog gap today, shown as one.
BPC-157 Yes 8–10 business days Injectable line; the cited record sits below.
TB-500 Yes 8–10 business days Injectable line; its section below carries the citations.
KPV No N/A Not dispensed by OrderlyMeds in any state; not an injectable line.
Epitalon Yes 8–10 business days Injectable line; see the cited section below.
MOTS-c Yes 8–10 business days Injectable line; its own federal record is stated below.

Reviewed November 16, 2026. Vermont gets the same treatment as the biggest states: every row reflects what we actually dispense, including the ones that say No.

BPC-157, TB-500, KPV, Epitalon & MOTS-c: the Vermont answer

For Vermont the catalog answer is the national one. Four of the five ship (BPC-157, TB-500, Epitalon, MOTS-c, each a compounded injectable), and KPV does not, in Vermont or anywhere. The part specific to this family of substances is federal, and it is cited inside each section below: that substance’s own FDA safety position, and the compounding pathway that currently applies to it. The five records differ, which is why there are five separately cited sections rather than one paragraph.

BPC-157 in Vermont

Vermont orders for BPC-157 are filled as a compounded injectable, on a patient-specific prescription, by a pharmacy registered for the state.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Vermont

TB-500 is dispensed to Vermont addresses as a compounded injectable, on a patient-specific prescription.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Vermont

KPV sits outside the OrderlyMeds formulary everywhere, because the peptide lines we carry are injectables and KPV is not compounded as one.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Vermont

Epitalon ships to Vermont as a compounded injectable.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Vermont

MOTS-c is part of what we dispense to Vermont, as a compounded injectable; read its federal record below on its own terms.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Vermont’s pharmacy regulators say about compounded medications

Two things distinguish Vermont’s paperwork. First, pharmacy oversight lives in the Secretary of State’s Office of Professional Regulation rather than in a health department. Second, Vermont attaches a specialty designation to registration: a nonresident pharmacy that compounds registers as a compounding pharmacy, full stop, not merely when compounded products are what it ships into the state. Its telehealth position, meanwhile, is written directly into the health code.

Vermont’s Board of Pharmacy administrative rules (effective February 1, 2026) govern compounding through registration and practice standards; they contain no GLP-1-specific or peptide-specific prohibition. Source: Vermont Board of Pharmacy — Administrative Rules (eff. Feb. 2026).

An out-of-state pharmacy shipping prescriptions to Vermont patients must register with the Office of Professional Regulation as a nonresident pharmacy, and a pharmacy that compounds must register with the compounding specialty designation regardless of which products it ships to Vermont. Source: Vermont OPR — Pharmacy registration forms & instructions.

Vermont law authorizes a licensed provider to prescribe after an appropriate examination performed in person or through telemedicine, and holds prescriptions issued via telemedicine to the same standard as traditional provider-patient settings (18 V.S.A. §9361). Source: 18 V.S.A. §9361 — Telemedicine.

In practice a Burlington or Montpelier order looks like any other OrderlyMeds order: eligibility check online, a telehealth evaluation with a provider authorized for Vermont, fulfillment by a nonresident-registered partner pharmacy carrying the designation Vermont asks of compounders, and delivery inside the published 8–10 business-day window. The price is the national one, and Vermont adds nothing to it.

Vermont availability FAQs

Can I get compounded GLP-1s delivered in Vermont?

Yes. Compounded semaglutide and compounded tirzepatide both ship to Vermont addresses, starting at $74/month for new semaglutide customers.

What is Vermont’s compounding designation about?

Vermont asks out-of-state pharmacies that compound to register under a compounding specialty designation, whatever they ship. It is a registration detail handled by the pharmacy, not a step you take, and the regulator section above cites it.

Do the research peptides ship to Vermont?

Four of five do: BPC-157, TB-500, Epitalon and MOTS-c, as compounded injectables on patient-specific prescriptions. KPV is not in our formulary in any state. Each line’s own cited federal record sits in its section above.

How fast do Vermont orders arrive?

Plan on the published 8–10 business days from signup, tracked door to door.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone